← Back to Search

Other

Tramiprosate for Alzheimer's Disease

Phase 3

Waitlist Available

Research Sponsored by Bellus Health Inc. - a GSK company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male or female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will study the long-term safety of Tramiprosate in patients with Alzheimer's disease.

Who is the study for?

This trial is for adults aged 50 or older with mild to moderate Alzheimer's who completed a previous 78-week study. They must live in the community (or assisted living with supervision) and have a reliable caregiver, be able to swallow tablets, and not be part of another drug trial.Check my eligibility

What is being tested?

The study is testing the long-term safety of Tramiprosate (3APS), previously studied in a Phase III trial, for patients with mild to moderate Alzheimer's disease. It's an open-label extension which means everyone gets the active drug and knows what they are receiving.See study design

What are the potential side effects?

While specific side effects aren't listed here, common ones associated with Alzheimer’s treatments may include nausea, diarrhea, insomnia, muscle cramps, fatigue. Participants will be monitored for any long-term safety concerns.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am over 50 and cannot have children (either through surgery or menopause).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To evaluate the long-term safety of Tramiprosate (3APS).

Secondary outcome measures

To provide additional long-term data on the efficacy of Tramiprosate (3APS).

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Bellus Health Inc. - a GSK companyLead Sponsor

17 Previous Clinical Trials

4,688 Total Patients Enrolled

Bellus Health IncLead Sponsor

15 Previous Clinical Trials

4,622 Total Patients Enrolled

Media Library

Tramiprosate (3APS) (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00314912 — Phase 3

Alzheimer's Disease Research Study Groups:

Alzheimer's Disease Clinical Trial 2023: Tramiprosate (3APS) Highlights & Side Effects. Trial Name: NCT00314912 — Phase 3

Tramiprosate (3APS) (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00314912 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots in this trial for new patients?

"No, this study is not recruiting patients right now, however, there are 551 other trials that are. This particular trial was first posted on May 1st, 2006 and last updated on July 13th, 2007 according to the information available on clinicaltrials.gov."

Answered by AI

Has this medication been deemed safe by the FDA?

"This treatment option was deemed safe by our team, as it is a Phase 3 trial. This means that not only is there data supporting its efficacy, but also that there have been multiple rounds of data supporting its safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

2006. "Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00314912.

All > Osa